Why the study?
Does esaxerenone added to existing renin-angiotensin system inhibitor therapy improve albuminuria in patients with type 2 diabetes and microalbuminuria?
Does esaxerenone added to existing renin-angiotensin system inhibitor therapy improve albuminuria in patients with type 2 diabetes and microalbuminuria?
Esaxerenone added to RAS inhibitors improves albuminuria outcomes in patients with type 2 diabetes and microalbuminuria.
Hypothesis-generating for esaxerenone in diabetic microalbuminuria; should not yet change practice pending randomized confirmation.
Adding esaxerenone to existing renin-angiotensin system inhibitor therapy in patients with type 2 diabetes and microalbuminuria increased the likelihood of albuminuria returning to normal levels, and reduced progression of albuminuria to higher levels.
No takes yet. Share an insight, caveat, or question.
Ito et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: